Bioceltix S.A.
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more
Bioceltix S.A. (BCX) - Total Assets
Latest total assets as of September 2025: zł30.17 Million PLN
Based on the latest financial reports, Bioceltix S.A. (BCX) holds total assets worth zł30.17 Million PLN as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioceltix S.A. - Total Assets Trend (2018–2024)
This chart illustrates how Bioceltix S.A.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bioceltix S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Bioceltix S.A.'s total assets of zł30.17 Million consist of 94.2% current assets and 5.8% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 80.4% |
| Accounts Receivable | zł4.97 Million | 11.9% |
| Inventory | zł14.00K | 0.0% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł0.00 | 0.0% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Bioceltix S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioceltix S.A.'s current assets represent 94.2% of total assets in 2024, an increase from 54.7% in 2018.
- Cash Position: Cash and equivalents constituted 80.4% of total assets in 2024, up from 47.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 11.9% of total assets.
Bioceltix S.A. Competitors by Total Assets
Key competitors of Bioceltix S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Bioceltix S.A. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bioceltix S.A. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bioceltix S.A. is currently not profitable relative to its asset base.
Bioceltix S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.83 | 15.50 | 3.65 |
| Quick Ratio | 8.83 | 15.50 | 3.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł23.26 Million | zł 38.99 Million | zł 6.72 Million |
Bioceltix S.A. - Advanced Valuation Insights
This section examines the relationship between Bioceltix S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.58 |
| Latest Market Cap to Assets Ratio | 1.70 |
| Asset Growth Rate (YoY) | 228.6% |
| Total Assets | zł41.85 Million |
| Market Capitalization | $71.31 Million USD |
Valuation Analysis
Above Book Valuation: The market values Bioceltix S.A.'s assets above their book value (1.70 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Bioceltix S.A.'s assets grew by 228.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bioceltix S.A. (2018–2024)
The table below shows the annual total assets of Bioceltix S.A. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł41.85 Million | +228.65% |
| 2023-12-31 | zł12.74 Million | +112.70% |
| 2022-12-31 | zł5.99 Million | -26.95% |
| 2021-12-31 | zł8.20 Million | +70.67% |
| 2020-12-31 | zł4.80 Million | +48.73% |
| 2019-12-31 | zł3.23 Million | -2.16% |
| 2018-12-31 | zł3.30 Million | -- |